FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3154014718> ?p ?o ?g. }

• W3154014718 abstract "Background: Imatinib is the gold standard in the treatment of chronic myeloid leukemia (CML) patients. Resistance to imatinib is interfering with patients’ responses and their survivals.&#x0D; Materials and Methods: We designed a systematic search to find relevant studies by applying appropriate keywords in PubMed, Web of science, Scopus, Ovid, ProQuest, Science direct and Google scholar for English studies. We also investigated the aforementioned terms’ correspondence in Magiran, Scientific information database (SID) and Google scholar for Persian articles.&#x0D; Results: 25 studies were selected for final analysis. Reported hematologic responses from adult studies ranged 86-99% and major molecular responses were estimated in 38.84% of our patients within 12 months of treatment. The most frequent reported adverse drug reactions (ADRs) were edema (n=5 studies, 100%) and fatigue and nausea (n=4 studies, 80%); ADR per capita ratio was 1.46. Only one study informed ADRs in pediatrics demonstrating 93% of patients experienced ADRs after receiving imatinib. Most of the Studies (n=4, 67% from 7 studies) considered BCR/ABL point mutation as main reason of imatinib resistance. Drug-binding site and P-loop regions were two common sites for BCR/ABL point mutation.&#x0D; Conclusion: Imatinib as the first line treatment for CML has been associated with proper and durable responses in Iranian adults and children CML patients. Moreover, Imatinib life-threatening adverse effects were reported uncommon. Various responses to modified regimens have been reported in resistant patients; therefore, individualized treatment based on mutation type could be recommended." @default.
• W3154014718 created "2021-04-26" @default.
• W3154014718 creator A5019399524 @default.
• W3154014718 creator A5024943846 @default.
• W3154014718 creator A5049347044 @default.
• W3154014718 creator A5077421143 @default.
• W3154014718 creator A5084113009 @default.
• W3154014718 date "2021-04-19" @default.
• W3154014718 modified "2023-10-16" @default.
• W3154014718 title "Imatinib Efficacy, Safety and Resistance in Iranian Patients with Chronic Myeloid Leukemia: A Review of Literature" @default.
• W3154014718 cites W1116689108 @default.
• W3154014718 cites W1510933939 @default.
• W3154014718 cites W1649173255 @default.
• W3154014718 cites W1889675684 @default.
• W3154014718 cites W1964827067 @default.
• W3154014718 cites W1968071128 @default.
• W3154014718 cites W1976972162 @default.
• W3154014718 cites W1977268219 @default.
• W3154014718 cites W1983032316 @default.
• W3154014718 cites W1984157617 @default.
• W3154014718 cites W1987239635 @default.
• W3154014718 cites W1991773845 @default.
• W3154014718 cites W1995618464 @default.
• W3154014718 cites W1995701940 @default.
• W3154014718 cites W2011377576 @default.
• W3154014718 cites W2011474502 @default.
• W3154014718 cites W2021648831 @default.
• W3154014718 cites W2024000841 @default.
• W3154014718 cites W2028959752 @default.
• W3154014718 cites W2031161823 @default.
• W3154014718 cites W2031888170 @default.
• W3154014718 cites W2032143394 @default.
• W3154014718 cites W2051728915 @default.
• W3154014718 cites W2052109174 @default.
• W3154014718 cites W2055502046 @default.
• W3154014718 cites W2056058740 @default.
• W3154014718 cites W2066113786 @default.
• W3154014718 cites W2068117867 @default.
• W3154014718 cites W2070179299 @default.
• W3154014718 cites W2074015360 @default.
• W3154014718 cites W2074417541 @default.
• W3154014718 cites W2074740152 @default.
• W3154014718 cites W2075709035 @default.
• W3154014718 cites W2076051136 @default.
• W3154014718 cites W2079446921 @default.
• W3154014718 cites W2091005492 @default.
• W3154014718 cites W2093531946 @default.
• W3154014718 cites W2095269243 @default.
• W3154014718 cites W2097799776 @default.
• W3154014718 cites W2099172974 @default.
• W3154014718 cites W2104177774 @default.
• W3154014718 cites W2107268345 @default.
• W3154014718 cites W2107419121 @default.
• W3154014718 cites W2115162935 @default.
• W3154014718 cites W2117792040 @default.
• W3154014718 cites W2121990442 @default.
• W3154014718 cites W2126246857 @default.
• W3154014718 cites W2131171876 @default.
• W3154014718 cites W2136373950 @default.
• W3154014718 cites W2166654361 @default.
• W3154014718 cites W2171722798 @default.
• W3154014718 cites W2181458496 @default.
• W3154014718 cites W2299676842 @default.
• W3154014718 cites W2329648702 @default.
• W3154014718 cites W2625444425 @default.
• W3154014718 cites W2797702561 @default.
• W3154014718 cites W2947506643 @default.
• W3154014718 cites W2977000670 @default.
• W3154014718 cites W856599574 @default.
• W3154014718 doi "https://doi.org/10.18502/ijhoscr.v15i2.6042" @default.
• W3154014718 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8381106" @default.
• W3154014718 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34466210" @default.
• W3154014718 hasPublicationYear "2021" @default.
• W3154014718 type Work @default.
• W3154014718 sameAs 3154014718 @default.
• W3154014718 citedByCount "0" @default.
• W3154014718 crossrefType "journal-article" @default.
• W3154014718 hasAuthorship W3154014718A5019399524 @default.
• W3154014718 hasAuthorship W3154014718A5024943846 @default.
• W3154014718 hasAuthorship W3154014718A5049347044 @default.
• W3154014718 hasAuthorship W3154014718A5077421143 @default.
• W3154014718 hasAuthorship W3154014718A5084113009 @default.
• W3154014718 hasBestOaLocation W31540147181 @default.
• W3154014718 hasConcept C114851261 @default.
• W3154014718 hasConcept C126322002 @default.
• W3154014718 hasConcept C143998085 @default.
• W3154014718 hasConcept C197934379 @default.
• W3154014718 hasConcept C2777413986 @default.
• W3154014718 hasConcept C2777583451 @default.
• W3154014718 hasConcept C2778729363 @default.
• W3154014718 hasConcept C2780580376 @default.
• W3154014718 hasConcept C71924100 @default.
• W3154014718 hasConcept C86803240 @default.
• W3154014718 hasConcept C89423630 @default.
• W3154014718 hasConceptScore W3154014718C114851261 @default.
• W3154014718 hasConceptScore W3154014718C126322002 @default.
• W3154014718 hasConceptScore W3154014718C143998085 @default.
• W3154014718 hasConceptScore W3154014718C197934379 @default.
• W3154014718 hasConceptScore W3154014718C2777413986 @default.
• W3154014718 hasConceptScore W3154014718C2777583451 @default.

• next